Vilin Bio Med Ltd (VILINBIO) — shareholding pattern, promoter holding, financials and share price
About Vilin Bio Med Ltd (VILINBIO)
Vilin Bio Med Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VILINBIO and on the BSE under scrip code 78871. Its ISIN is INE0L4V01013.
Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products [1]
Vilin Bio Med Limited is primarily engaged in manufacturing pharmaceutical products, specializing in both Beta-Lactam and Non-Beta-Lactam medicines.
The company boasts a robust portfolio of over 1000 drug approvals across diabetic, neurological, and cardiovascular therapeutic areas.
Listed peers in Pharmaceuticals: Bharat Immunological & Biological Corporation Ltd, Sunil Healthcare Ltd, Source Natural Foods & Herbal Supplements Ltd, Onyx Biotec Ltd, Phaarmasia Ltd, Asston Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹46 a share on 10 Jul 2026, Vilin Bio Med Ltd (VILINBIO) was valued at a price-to-earnings ratio of 36.35x against an industry P/E of 36.41x and a price-to-book of 2.47x on a book value of ₹18.6 per share. Solomo computes return on equity of 6.8% and return on capital employed of 10.18% from filed results.
- P/E
- 36.35x
- Industry P/E
- 36.41x
- P/B
- 2.47x
- EPS (TTM)
- ₹0.16
- Book value / share
- ₹18.6
- ROE
- 6.8%
- ROCE
- 10.18%
- ROA
- 5.52%
- Debt / equity
- 0.01x
- Dividend yield
- 0%
- EBITDA margin
- 7.57%
- 52-week range
- ₹18.95 – ₹54.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Vilin Bio Med Ltd (VILINBIO) reported revenue of ₹42.26 crore, net profit of ₹1.93 crore and earnings per share of ₹1.27. That compares with revenue of ₹14.81 crore and net profit of ₹0.22 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹32.6 crore and net profit ₹1.78 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 11.21 | 12.31 | 15.8 | 14.81 | 42.26 |
| Net profit (₹ cr) | 0.03 | 1.25 | 0.16 | 0.22 | 1.93 |
| EPS (₹) | 0.09 | 1.26 | 0.11 | 0.16 | 1.27 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | -2.51% | 9.71% | -6.27% |
| Profit growth | 6.62% | 88.07% | 37.50% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 56.65% of Vilin Bio Med Ltd (VILINBIO) (down 2.92 pp QoQ). Market capitalisation was ₹70 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2023.
Largest disclosed public shareholders in Jun 2026: ENSPIRE INSTITUTE OF PROFESSIONAL STUDIES LLP 4.39%, AMN VENTURES LLP 4.13%, PERCY HOMI ITALIA 3.92%, KRISHNA 2.86%, SRINIVASA REDDY DEVIREDDY 1.87%, BOSCO ARMANDO MENEZES 1.08%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 56.65% | - | - | - | - |
| Mar 2026 | 59.57% | - | - | - | - |
| Dec 2025 | 63.65% | - | - | - | - |
| Sep 2025 | 63.89% | - | - | - | - |
| Jun 2025 | 63.89% | - | - | - | - |
| Mar 2025 | 63.89% | - | - | - | - |
| Sep 2024 | 64.09% | - | - | - | - |
| Mar 2024 | 64.52% | - | - | - | - |